|
MOUNTAINSIDE, NJ - Proteonomix, Inc. (PINKSHEETS: PROT) announces that it has formed a wholly-owned subsidiary, StromaCel, Inc.
The mission of StromaCel is to develop therapies using StromaCels. StromaCels are key components of tissues and provide critical cytokines and growth factors as well as the cellular microenvironment for normal homeostasis. A cytokine is a small protein released by cells that affects the interactions and communications between cells and the behavior of cells. A growth factor is a naturally occurring substance capable of stimulating cellular growth, proliferation and differentiation. Homeostasis is a self-regulating process by which a biological system maintains stability while adjusting to changing conditions. StromaCels provide a niche proliferation environment for stem cells.
StromaCel's goal is to study the basic cellular properties of StromaCels and to identify the utility of cellular and protein derivatives in disease repair.
StromaCel is the fifth subsidiary of Proteonomix. National Stem Cell, Inc. is Proteonomix' operating subsidiary. The Sperm Bank of New York, Inc., engaged in reproductive tissue banking, including sperm, ova, ovarian tissue and testicular tissue, is a subsidiary of National Stem Cell, Inc. Proteoderm has developed and has begun to manufacture and distribute a line of anti-aging cosmeceuticals based on stem cell derivatives. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Going forward, Proteonomix intends to create and dedicate a subsidiary to each of its technologies.
About Proteonomix, Inc
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteonomix has facilities at a number of academic institutions. Please visit www.proteonomix.com, www.proteoderm.com, www.pinksheets.com and www.sec.gov for further information about Proteonomix
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release relating to the development and potential therapeutic use of StromaCels constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made. |
